Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SAR442168 versus teriflunomide in relapsing multiple sclerosis
2020-000644-55Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR442168 with Aubagio (2 arms). Primary endpoint: Annualized adjudicated relapse rate. Started Jun 2020; status: completed.
02
Drugs
tolebrutinibteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-000644-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000644-55.